Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

Gynaecological cancers

2972 - The Exposure-Response Relationship of Niraparib in Patients with gBRCAmut and Non-gBRCAmut: Results from the ENGOT-OV16/NOVA Trial

Date

09 Sep 2017

Session

Gynaecological cancers

Presenters

Jing Wang

Citation

Annals of Oncology (2017) 28 (suppl_5): v330-v354. 10.1093/annonc/mdx372

Authors

J. Wang1, Z. Zhang2, M.R. Mirza3, L. Gilbert4, M. Fabbro5, A.V. Tinker6, X. Wang2, A. Redondo7, J.S. Berek8, L. Woelber9, H.S. Pentikis10, K.N. Moore11, D. Lorusso12, B. Benigno13, S.J. Hazard14, P. Follana15, B.J. Rimel16, U.A. Matulonis17, S. Agarwal14, V. Kansra2

Author affiliations

  • 1 Clinical Pharmacology, TESARO, Inc., 02451 - Waltham/US
  • 2 Clinical Pharmacology, TESARO, Inc., Waltham/US
  • 3 Oncology, Nordic Society of Gynecologic Oncology (NSGO) and Rigshospitalet, Copenhagen University Hospital, Copenhagen/DK
  • 4 Oncology, McGill University Health Centre, Montreal/CA
  • 5 Oncology, Groupe d'Investigateurs Nationaux pour l'Etude des Cancers Ovariens (GINECO) and Institut du Cancer de Montpellier, 34298 - Montpellier/FR
  • 6 Systemic Therapy, BC Cancer Agency Vancouver, V5Z4E6 - Vancouver/CA
  • 7 Oncology, Grupo Español de Investigación en Cáncer de Ovario (GEICO) & Hospital Universitario La Paz, Madrid/ES
  • 8 Gynecologic Oncology, Stanford Cancer Institute, Palo Alto/US
  • 9 Gynaecology And Gynaecologic Oncology, Arbeitsgemeinschaft Gynäkologische Onkologie (AGO) and Universitätsklinikum Hamburg-Eppendorf, Hamburg/DE
  • 10 Clinical Pharmacology, SAJE Consulting LLC, Baltimore/US
  • 11 Obstetrics And Gynecology, Stephenson Cancer Center, University of Oklahoma HSC; Sarah Cannon Research Institute (Nashville, TN), 73104 - Oklahoma City/US
  • 12 Gynecologic Oncology, Multicenter Italian Trials in Ovarian cancer/Mario Negri Gynecologic Oncology (MITO/MaNGO) & Fondazione IRCCS National Cancer Institute, 20133 - Milan/IT
  • 13 Gynecologic Oncology, Northside Hospital, Atlanta/US
  • 14 Clinical Science, TESARO, Inc., 2451 - Waltham/US
  • 15 Hématologie - Oncologie Médicale, Groupe d'Investigateurs Nationaux pour l'Etude des Cancers Ovariens (GINECO) & Centre Antoine Lacassagne, 6100 - Nice/FR
  • 16 Obstetrics & Gynecology, Cedars-Sinai Medical Center, West Hollywood/US
  • 17 Gynecologic Oncology, Dana-Farber Cancer Institute, 2115 - Boston/US
More

Resources

Abstract 2972

Background

Niraparib (ZEJULA™) is a selective PARP1/2 inhibitor approved for maintenance treatment of adults with recurrent ovarian cancer who are in a complete or partial response to platinum-based chemotherapy. In preclinical studies, niraparib concentrates in the tumor versus plasma, delivering ≥90% durable PARP1/2 inhibition and a persistent antitumor effect. We report the relationship between exposure and response of niraparib in patients (pts) enrolled in the ENGOT-OV16/NOVA trial.

Methods

Preliminary modeling for niraparib was performed using Phase 1 study data (N = 104) to identify the initial parameters for the pharmacokinetic model, which was developed using combined Phase 1 and Phase 3 data (N = 512 pts) and the first-order conditional estimation with interaction method within NONMEM. Exposure-efficacy relationships were evaluated in the gBRCAmut and non-gBRCAmut cohorts separately; the efficacy was compared in pts with high exposure (> median exposure) vs low exposure (≤ median exposure). Maximum plasma concentration (Cmax) and area under the curve over the dosing interval (AUCtau) at steady state (SS) were the exposure metrics. Progression-free survival (PFS) was used as efficacy endpoint. Hazard ratios (HRs) and 95% confidence intervals (CI) for the low and high niraparib exposure groups in each cohort were provided, with exposure group as the independent variable and PFS as the dependent variable. Exposure and safety data of gBRCAmut and non-gBRCAmut cohorts were combined to evaluate exposure-safety relationships using logistic regression.

Results

In the gBRCAmut cohort, the HR was 0.91 (95% CI, 0.54-1.52) for niraparib exposure as measured by the SS AUCtau for pts in the high exposure vs. the low exposure group. In the gBRCAmut cohort, the HR was 0.70 (95% CI, 0.49-0.99). Logistic regression analysis did not show any significant relationship between the incidence of thrombocytopenia or anemia Grade ≥ 3 and the SS Cmax or AUC increase.

Conclusions

Observed exposure-response relationships support the selection of 300 mg as the starting dose in both gBRCAmut and non-gBRCAmut pt populations. A trend towards increased efficacy associated with increased exposure was observed in the non-gBRCAmut cohort.

Clinical trial identification

NCT01847274

Legal entity responsible for the study

TESARO, Inc.

Funding

TESARO, Inc.

Disclosure

J. Wang, Z-Y. Zhang, X. Wang, S. Agarwal: Employment: Tesaro Stock: Tesaro. M.R. Mirza: Consulting or Advisory Role: Roche, Clovis Oncology, AstraZeneca, Tesaro. L. Gilbert: Honoraria: AstraZeneca, Advaxis Consulting/Advisory Role: AstraZeneca, Advaxis. A.V. Tinker: Consulting/Advisory: AstraZeneca. J.S. Berek: Consulting/Advisory: Atara Biotherapeutics. H.S. Pentikis, V. Kansra: Advisory board or board of directors: Tesaro Consulting: Tesaro. B. Benigno: Honoraria: AstraZeneca, Insys Therapeutics Research funding: Tesaro. S.J. Hazard: Employment: Tesaro, Genentech/Roche Stock: Tesaro, Genentech/Roche Travel, Accommodations, Expenses: Tesaro, Genentech/Roche. B.J. Rimel: Consulting/Advisory Role: AstraZeneca, Tesaro, Genentech/Roche Honoraria: Genentech. U.A. Matulonis: Consulting/Advisory: Merck KGaA, AstraZeneca, Immunogen, Tesaro, Genentech. All other authors have declared no conflicts of interest.

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings
  • Necessary cookies enable core functionality. The website cannot function properly without these cookies, and you can only disable them by changing your browser preferences.